{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:11:12Z","timestamp":1792606272561,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["#2018PG-CD007"],"award-info":[{"award-number":["#2018PG-CD007"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Real-world data on outcomes of patients with newly diagnosed Crohn\u2019s disease (ndCD) is limited. We aimed to assess the achievement of corticosteroid-free clinical remission (CS-free CR) and other therapeutic targets 1 year after diagnosis in a cohort of patients with ndCD treated by a multidisciplinary team (MDT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective observational cohort study was conducted on consecutive treatment-na\u00efve adults with ndCD. Patients received management at the treating physician\u2019s discretion, along with a tailored nutritional plan provided by an inflammatory bowel disease (IBD)-oriented dietitian. Patients were guided and educated by an IBD nurse, with flexible communication access to the IBD team. Therapeutic targets were assessed at 1 year. Multivariable logistic regression was used to evaluate predictors of CS-free CR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-six patients (50% female) with a median age of 27 (22\u201339) years were eligible. Over 75% of patients were assessed by IBD-oriented dietitians and the IBD nurse. Within a median of 4.3 (2.5\u20136.7) months from diagnosis 60.5% initiated biologics (96% anti- tumor necrosis factor). Dietary intervention was applied to 77.6% of the cohort, either monotherapy (33.9%) or add-on (66.1%). At 1 year, 64.5% of patients achieved sustained CS-free CR, 56.6% biochemical remission, 55.8% endoscopic response, 44.2% endoscopic remission, 30.8% deep remission, and in 39.5% there was an improvement in health-related quality of life (HRQoL). Predictors for CS-free CR were uncomplicated phenotype (B1\/P0), lower body mass index, and lower patient-reported outcome 2 scores at diagnosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a real-world setting at a tertiary medical center, a cohort of ndCD patients treated by an MDT resulted in favorable 1-year outcomes. Over 60% achieved CS-free CR, along with significant improvements in biomarkers and HRQoL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otad064","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:27:52Z","timestamp":1697560072000},"source":"Crossref","is-referenced-by-count":12,"title":["A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn\u2019s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-5271","authenticated-orcid":false,"given":"Henit","family":"Yanai","sequence":"first","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-4520","authenticated-orcid":false,"given":"Tali","family":"Sharar Fischler","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-2840","authenticated-orcid":false,"given":"Idan","family":"Goren","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"},{"name":"Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar","family":"Eran-Banai","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E","family":"Ollech","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifat","family":"Snir","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Broitman","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Barkan","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Pfeffer-Gik","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7758-6466","authenticated-orcid":false,"given":"Lihi","family":"Godny","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Kutokov","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Friedeberg","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maor H","family":"Pauker","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren Masha","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"},{"name":"Felsenstein Medical Research Center, Faculty of Medicine , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avni-Biron","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"IBD Center, Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"},{"name":"Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"issue":"4","key":"2023110712315112700_CIT0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn\u2019s disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2023110712315112700_CIT0002","first-page":"274","article-title":"Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn\u2019s disease and its impact on disease outcome","volume":"11","author":"Fiorino","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2023110712315112700_CIT0003","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology."},{"issue":"3","key":"2023110712315112700_CIT0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2023110712315112700_CIT0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.21010","article-title":"Disability in inflammatory bowel diseases: developing ICF core sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health","volume":"16","author":"Peyrin-Biroulet","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2023110712315112700_CIT0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn\u2019s disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology."},{"issue":"5","key":"2023110712315112700_CIT0007","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting \u00adtherapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"12","key":"2023110712315112700_CIT0008","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ibd.22925","article-title":"Response to biologic therapy in Crohn\u2019s disease is improved with early treatment: an analysis of health claims data","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"9613","key":"2023110712315112700_CIT0009","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"10114","key":"2023110712315112700_CIT0010","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"10","key":"2023110712315112700_CIT0011","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/ecco-jcc\/jjz057","article-title":"Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn\u2019s disease: 10-year-follow-up data from the Swiss IBD Cohort Study","volume":"13","author":"Frei","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2023110712315112700_CIT0012","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ecco-jcc\/jjaa044","article-title":"Temporal trends in surgical resection rates and biologic prescribing in Crohn\u2019s disease: a population-based cohort study","volume":"14","author":"Jenkinson","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"10006","key":"2023110712315112700_CIT0013","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2023110712315112700_CIT0014","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of care standards in inflammatory bowel diseases: a European Crohn\u2019s and Colitis Organisation [ECCO] position paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2023110712315112700_CIT0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2023110712315112700_CIT0016","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2023110712315112700_CIT0017","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ng.3755","article-title":"Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn\u2019s disease","volume":"49","author":"Lee","year":"2017","journal-title":"Nat Genet."},{"issue":"15","key":"2023110712315112700_CIT0018","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"2023110712315112700_CIT0019","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"issue":"20","key":"2023110712315112700_CIT0020","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"9317","key":"2023110712315112700_CIT0021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"issue":"8","key":"2023110712315112700_CIT0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"10342","key":"2023110712315112700_CIT0023","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet."},{"issue":"5","key":"2023110712315112700_CIT0024","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.17092","article-title":"Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient-mix","volume":"56","author":"Atia","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2023110712315112700_CIT0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2023110712315112700_CIT0026","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ecco-jcc\/jjab204","article-title":"Improved outcomes of paediatric and adult Crohn\u2019s disease and association with emerging use of biologics\u2014a nationwide study from the Epi-IIRN","volume":"16","author":"Atia","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2023110712315112700_CIT0027","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MCG.0000000000001490","article-title":"Specialized emergency department assessment and multidisciplinary intervention after discharge improve management of patients with inflammatory bowel diseases","volume":"56","author":"Goren","year":"2022","journal-title":"J Clin Gastroenterol."},{"key":"2023110712315112700_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848211053112","article-title":"Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic","volume":"14","author":"Yanai","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"10098","key":"2023110712315112700_CIT0029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial","volume":"390","author":"de Jong","year":"2017","journal-title":"Lancet."},{"issue":"5","key":"2023110712315112700_CIT0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.crohns.2013.09.018","article-title":"The effect of an inflammatory bowel disease nurse position on service delivery","volume":"8","author":"Leach","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2023110712315112700_CIT0031","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/gutjnl-2022-328174","article-title":"Lifestyle factors for the prevention of inflammatory bowel disease","volume":"72","author":"Emily","year":"2023","journal-title":"Gut."},{"issue":"1","key":"2023110712315112700_CIT0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S2468-1253(21)00299-5","article-title":"The Crohn\u2019s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn\u2019s disease (CDED-AD): an open-label, pilot, randomised trial","volume":"7","author":"Yanai","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2023110712315112700_CIT0033","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2023110712315112700_CIT0034","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.cgh.2021.04.006","article-title":"Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic na\u00efve Crohn\u2019s disease","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2023110712315112700_CIT0035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cgh.2022.02.044","article-title":"Net remission rates with biologic treatment in Crohn\u2019s disease: a reappraisal of the clinical trial data","volume":"21","author":"Kayal","year":"2022","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otad064\/52217825\/otad064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/4\/otad064\/52776888\/otad064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/4\/otad064\/52776888\/otad064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T12:32:29Z","timestamp":1699360349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otad064\/7321175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otad064","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,10,1]]},"article-number":"otad064"}}